FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555963297> ?p ?o ?g. }

• W2555963297 endingPage "130" @default.
• W2555963297 startingPage "130" @default.
• W2555963297 abstract "Abstract Presently, there is no standard second-line regimen for patients (pts) with diffuse large B-cell lymphoma (DLBCL) who cannot undergo stem cell transplantation. Since yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) is highly active in pts with follicular lymphoma, we wished to establish whether it is also effective in pts with relapsed DLBCL. We therefore conducted a prospective, single-arm, open-label, non-randomized, multicenter phase II trial to evaluate the efficacy and safety of 90Y ibritumomab tiuxetan in elderly pts with histologically confirmed first relapsed or primary refractory DLBCL not appropriate for autologous stem cell transplantation. Pts were divided into 2 groups: those previously treated with chemotherapy alone [Group A, n=76], and those previously treated with chemotherapy and rituximab [Group B, n=28]. Pts in Group A were further divided into 3 strata: pts with primary refractory disease (stratum 1, n= 33), pts relapsing within a year from presentation (stratum 2, n=10), and those relapsing more than 1 year from presentation (stratum 3, n=33). All pts were to receive a single dose of 90Y ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) up to a maximum dose of 1184 MBq (32 mCi). The primary endpoint was overall response (ORR) assessed by using IWNHL criteria at Weeks 6, 12, and 24. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). 104 pts were included. Three pts progressed after the first rituximab dose and in 1 patient the 111In labeling procedure failed; 103 pts were evaluable for efficacy and 104 for safety. An ORR of 44% was observed in the entire study population. In Group A, the ORR was 52% in stratum 1, 40% in stratum 2, 58% in stratum 3. In Group B, where 37% of pts were refractory to CHOP-rituximab, the ORR was 19%. The median PFS was 5.9, 2.3, and 6.2 months in strata 1, 2, 3 of Group A, respectively; the median PFS for Group B was 1.6 months. Median OS in Group A was 22.4 months in stratum 3 and has not yet been reached at a maximum follow-up time of 32 months in strata 1&2. Median OS was 4.5 months for Group B. Adverse events (AEs) with the exception of hematologic AEs were generally mild or moderate (CTC grade 1 and 2). There were 4 deaths due to SAEs. Three pts died of suspected cerebral hemorrhage, preceded by CTC grade 4 thrombocytopenias; another died of bleeding from a duodenal ulcer 280 days after the start of study medication, but this AE was determined not to be related to the study drug. The incidence of severe infection is low with 7% of pts hospitalized for infection during the study. In conclusion, 90Y ibritumomab tiuxetan has useful activity in the treatment of relapsed/refractory DLBCL, with no unexpected toxicities observed. The results of this study support a further evaluation of 90Y ibritumomab tiuxetan in combination with chemotherapy or immuno-chemotherapy earlier in the time course of DLBCL." @default.
• W2555963297 created "2016-11-30" @default.
• W2555963297 creator A5002567433 @default.
• W2555963297 creator A5017931241 @default.
• W2555963297 creator A5029311961 @default.
• W2555963297 creator A5034043513 @default.
• W2555963297 creator A5046226959 @default.
• W2555963297 creator A5047468243 @default.
• W2555963297 creator A5051605599 @default.
• W2555963297 creator A5058751095 @default.
• W2555963297 creator A5058954518 @default.
• W2555963297 creator A5064728742 @default.
• W2555963297 creator A5066925260 @default.
• W2555963297 creator A5081642625 @default.
• W2555963297 creator A5082018030 @default.
• W2555963297 creator A5091882595 @default.
• W2555963297 date "2004-11-16" @default.
• W2555963297 modified "2023-10-01" @default.
• W2555963297 title "Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial." @default.
• W2555963297 doi "https://doi.org/10.1182/blood.v104.11.130.130" @default.
• W2555963297 hasPublicationYear "2004" @default.
• W2555963297 type Work @default.
• W2555963297 sameAs 2555963297 @default.
• W2555963297 citedByCount "20" @default.
• W2555963297 countsByYear W25559632972015 @default.
• W2555963297 crossrefType "journal-article" @default.
• W2555963297 hasAuthorship W2555963297A5002567433 @default.
• W2555963297 hasAuthorship W2555963297A5017931241 @default.
• W2555963297 hasAuthorship W2555963297A5029311961 @default.
• W2555963297 hasAuthorship W2555963297A5034043513 @default.
• W2555963297 hasAuthorship W2555963297A5046226959 @default.
• W2555963297 hasAuthorship W2555963297A5047468243 @default.
• W2555963297 hasAuthorship W2555963297A5051605599 @default.
• W2555963297 hasAuthorship W2555963297A5058751095 @default.
• W2555963297 hasAuthorship W2555963297A5058954518 @default.
• W2555963297 hasAuthorship W2555963297A5064728742 @default.
• W2555963297 hasAuthorship W2555963297A5066925260 @default.
• W2555963297 hasAuthorship W2555963297A5081642625 @default.
• W2555963297 hasAuthorship W2555963297A5082018030 @default.
• W2555963297 hasAuthorship W2555963297A5091882595 @default.
• W2555963297 hasConcept C126322002 @default.
• W2555963297 hasConcept C141071460 @default.
• W2555963297 hasConcept C143998085 @default.
• W2555963297 hasConcept C159654299 @default.
• W2555963297 hasConcept C203014093 @default.
• W2555963297 hasConcept C203092338 @default.
• W2555963297 hasConcept C2776146153 @default.
• W2555963297 hasConcept C2776694085 @default.
• W2555963297 hasConcept C2777058707 @default.
• W2555963297 hasConcept C2778336483 @default.
• W2555963297 hasConcept C2778515704 @default.
• W2555963297 hasConcept C2778559949 @default.
• W2555963297 hasConcept C2779050716 @default.
• W2555963297 hasConcept C2779338263 @default.
• W2555963297 hasConcept C2780653079 @default.
• W2555963297 hasConcept C2781413609 @default.
• W2555963297 hasConcept C2911091166 @default.
• W2555963297 hasConcept C31760486 @default.
• W2555963297 hasConcept C535046627 @default.
• W2555963297 hasConcept C542903549 @default.
• W2555963297 hasConcept C71924100 @default.
• W2555963297 hasConcept C90924648 @default.
• W2555963297 hasConceptScore W2555963297C126322002 @default.
• W2555963297 hasConceptScore W2555963297C141071460 @default.
• W2555963297 hasConceptScore W2555963297C143998085 @default.
• W2555963297 hasConceptScore W2555963297C159654299 @default.
• W2555963297 hasConceptScore W2555963297C203014093 @default.
• W2555963297 hasConceptScore W2555963297C203092338 @default.
• W2555963297 hasConceptScore W2555963297C2776146153 @default.
• W2555963297 hasConceptScore W2555963297C2776694085 @default.
• W2555963297 hasConceptScore W2555963297C2777058707 @default.
• W2555963297 hasConceptScore W2555963297C2778336483 @default.
• W2555963297 hasConceptScore W2555963297C2778515704 @default.
• W2555963297 hasConceptScore W2555963297C2778559949 @default.
• W2555963297 hasConceptScore W2555963297C2779050716 @default.
• W2555963297 hasConceptScore W2555963297C2779338263 @default.
• W2555963297 hasConceptScore W2555963297C2780653079 @default.
• W2555963297 hasConceptScore W2555963297C2781413609 @default.
• W2555963297 hasConceptScore W2555963297C2911091166 @default.
• W2555963297 hasConceptScore W2555963297C31760486 @default.
• W2555963297 hasConceptScore W2555963297C535046627 @default.
• W2555963297 hasConceptScore W2555963297C542903549 @default.
• W2555963297 hasConceptScore W2555963297C71924100 @default.
• W2555963297 hasConceptScore W2555963297C90924648 @default.
• W2555963297 hasIssue "11" @default.
• W2555963297 hasLocation W25559632971 @default.
• W2555963297 hasOpenAccess W2555963297 @default.
• W2555963297 hasPrimaryLocation W25559632971 @default.
• W2555963297 hasRelatedWork W2033236745 @default.
• W2555963297 hasRelatedWork W2074506590 @default.
• W2555963297 hasRelatedWork W2107990794 @default.
• W2555963297 hasRelatedWork W2418195638 @default.
• W2555963297 hasRelatedWork W2546713081 @default.
• W2555963297 hasRelatedWork W2555963297 @default.
• W2555963297 hasRelatedWork W2588576916 @default.
• W2555963297 hasRelatedWork W2589168429 @default.
• W2555963297 hasRelatedWork W2845072372 @default.
• W2555963297 hasRelatedWork W88155656 @default.

• next